ES2359031T3
(es)
|
1996-08-08 |
2011-05-17 |
Amylin Pharmaceuticals, Inc. |
Composición farmacéutica que comprende un péptido de exendina-4.
|
JP4798814B2
(ja)
*
|
1997-01-07 |
2011-10-19 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
食物摂取低減用のエキセンジンおよびそのアゴニストの使用
|
DK1019077T4
(da)
*
|
1997-08-08 |
2011-03-07 |
Amylin Pharmaceuticals Inc |
Hidtil ukendte exendinagonistforbindelser
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
ATE381939T1
(de)
*
|
1997-11-14 |
2008-01-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
EP1938830A1
(en)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
DK1032587T4
(da)
†
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
EP1941900A1
(en)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
EP1840134B1
(en)
|
1998-02-27 |
2016-04-13 |
Novo Nordisk A/S |
GLP-1 derivatives
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
TR200100079T2
(tr)
|
1998-06-12 |
2001-06-21 |
Bionebraska, Inc. |
Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
|
EP1306091A3
(en)
|
1998-07-31 |
2003-05-21 |
Novo Nordisk A/S |
Stimulation of beta cell proliferation
|
EP1140145B2
(en)
*
|
1999-01-14 |
2019-05-15 |
Amylin Pharmaceuticals, LLC |
Novel exendin agonist formulations and methods of administration thereof
|
WO2000041548A2
(en)
*
|
1999-01-14 |
2000-07-20 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
EP1175443A1
(en)
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
ES2209885T3
(es)
*
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
JP2003525908A
(ja)
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
血清脂質の低下
|
WO2002047716A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
EP1360202B1
(en)
|
2001-02-16 |
2008-05-21 |
ConjuChem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
DE60228972D1
(de)
*
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
PL377591A1
(pl)
*
|
2002-10-02 |
2006-02-06 |
Zealand Pharma A/S |
Stabilizowane związki eksendyny-4
|
AU2003286472A1
(en)
*
|
2002-10-17 |
2004-05-04 |
Alkermes Controlled Therapeutics, Inc. Ii |
Microencapsulation and sustained release of biologically active polypeptides
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP1631308B1
(en)
*
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
KR101135244B1
(ko)
*
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
EP2298337B1
(en)
|
2003-12-09 |
2017-02-22 |
Novo Nordisk A/S |
Regulation of food preference using GLP-1 agonists
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
US20050143303A1
(en)
*
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
EP2100904B1
(en)
*
|
2004-04-23 |
2010-07-07 |
ConjuChem Biotechnologies Inc. |
Solid phase for use in a method for the purification of albumin conjugates
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1アゴニストを用いた薬剤誘発性肥満の中和
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
JP4785206B2
(ja)
*
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン(Exendins)及びその使用
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
ES2572952T3
(es)
|
2005-11-07 |
2016-06-03 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
WO2007061434A2
(en)
*
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
US20080318861A1
(en)
*
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
EP1976876A4
(en)
*
|
2005-12-22 |
2010-01-13 |
Conjuchem Biotechnologies Inc |
PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
|
CA2651855C
(en)
|
2006-05-30 |
2011-08-02 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
ES2422864T3
(es)
|
2006-08-09 |
2013-09-16 |
Intarcia Therapeutics, Inc |
Sistemas de liberación osmótica y unidades de pistón
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
KR100746658B1
(ko)
|
2007-04-23 |
2007-08-06 |
성균관대학교산학협력단 |
소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
|
PT2157967E
(pt)
|
2007-04-23 |
2013-04-03 |
Intarcia Therapeutics Inc |
Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
JP2010538069A
(ja)
*
|
2007-09-07 |
2010-12-09 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
エキセンディン−4およびエキセンディン−3の類似体
|
JP5771005B2
(ja)
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
|
CA2708762A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
US20090221453A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Sumitra Mukhopadhyay |
Treatment Fluid With Oxidizer Breaker System and Method
|
CL2009001425A1
(es)
|
2008-06-17 |
2010-04-30 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
|
CL2009001424A1
(es)
|
2008-06-17 |
2010-04-30 |
Univ Indiana Res & Tech Corp |
Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
|
HUE037449T2
(hu)
|
2008-10-17 |
2018-08-28 |
Sanofi Aventis Deutschland |
Egy inzulin és egy GLP-1 agonista kombinációja
|
WO2010066734A1
(en)
|
2008-12-08 |
2010-06-17 |
Novo Nordisk A/S |
Counter current purification of polypeptides
|
AU2009327418A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
CN101463078B
(zh)
*
|
2009-01-12 |
2011-07-27 |
华东师范大学 |
一种Exendin-4衍生物及其固相化学合成
|
IN2012DN00377A
(da)
|
2009-06-16 |
2015-08-21 |
Univ Indiana Res & Tech Corp |
|
KR101823699B1
(ko)
|
2009-09-28 |
2018-01-30 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
WO2011058082A1
(de)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
|
AR080669A1
(es)
|
2009-11-13 |
2012-05-02 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
|
EP2504019A2
(en)
|
2009-11-25 |
2012-10-03 |
ArisGen SA |
Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
|
US8703701B2
(en)
*
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
US8551946B2
(en)
|
2010-01-27 |
2013-10-08 |
Indiana University Research And Technology Corporation |
Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
EP2542565A1
(en)
|
2010-03-01 |
2013-01-09 |
Novo Nordisk A/S |
Preparative rp-hplc method for purifying peptides
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
ES2606554T3
(es)
|
2010-08-30 |
2017-03-24 |
Sanofi-Aventis Deutschland Gmbh |
Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EP2691973B1
(en)
*
|
2011-03-31 |
2019-05-08 |
DH Technologies Development Pte. Ltd. |
Composition, method, and kit for calibrating a mass spectrometer
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
MX347703B
(es)
|
2011-06-22 |
2017-05-09 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1.
|
MX2013015168A
(es)
|
2011-06-22 |
2014-03-31 |
Univ Indiana Res & Tech Corp |
Co-agonista del receptor de glucagon/glp-1.
|
BR112014004726A2
(pt)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
EP2788027A2
(en)
|
2011-12-09 |
2014-10-15 |
Novo Nordisk A/S |
Glp-1 agonists
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
KR20150023013A
(ko)
|
2012-06-21 |
2015-03-04 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
수용체 활성을 나타내는 글루카곤 유사체
|
AU2013295035B2
(en)
|
2012-07-23 |
2017-08-03 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
KR20140088837A
(ko)
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
RS57632B1
(sr)
|
2013-10-17 |
2018-11-30 |
Zealand Pharma As |
Acilovani analozi glukagona
|
EP3066117B1
(en)
|
2013-11-06 |
2019-01-02 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
CA2932477C
(en)
|
2013-12-06 |
2023-10-10 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
SG11201604708VA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CN105899190B
(zh)
|
2014-01-09 |
2022-06-14 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|
AU2015205624A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
PL3229828T3
(pl)
|
2014-12-12 |
2023-07-31 |
Sanofi-Aventis Deutschland Gmbh |
Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
EP3283507B8
(en)
|
2015-04-16 |
2019-11-13 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
CN105753963B
(zh)
*
|
2016-04-13 |
2019-08-30 |
中国药科大学 |
高活性艾塞那肽类似物及其医药应用
|
KR102574993B1
(ko)
|
2016-05-16 |
2023-09-06 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
ES2979184T3
(es)
|
2016-12-09 |
2024-09-24 |
Zealand Pharma As |
Agonistas duales de glp-1/glp-2 acilados
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
CN109485720A
(zh)
*
|
2017-09-11 |
2019-03-19 |
中国药科大学 |
口服降血糖多肽、其脂肪酸修饰衍生物以及用途
|
CN115947849A
(zh)
|
2018-12-21 |
2023-04-11 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
CN116606367A
(zh)
*
|
2022-05-31 |
2023-08-18 |
南京盛德瑞尔医药科技有限公司 |
长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
|